CareDx, Inc. (CDNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 6, 2025, by CareDx, Inc., a Delaware corporation. The filing primarily addresses the announcement of financial results for the quarter ended June 30, 2025, and significant changes in executive leadership.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended June 30, 2025. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release or the upcoming Form 10-Q for detailed financial data.
Material Changes and Executive Leadership
The most significant material change reported is the transition of the Chief Financial Officer (CFO) role:
- Departure: Abhishek Jain retired as CFO effective August 6, 2025. The departure is not related to any disagreement regarding financial statements or disclosures.
- Appointment: Nathan Smith was appointed as CFO, effective August 7, 2025. Mr. Smith previously served as CFO for Win Brands Group and Inmedix, Inc., and held senior finance roles at Myriad Genetics, Inc.
Compensation, Severance, and Agreements
Nathan Smith (New CFO):
- Base Salary: $400,000 annualized.
- Bonus: Eligible for an annual performance bonus of up to 50% of base salary.
- Equity: Granted 42,000 Restricted Stock Units (RSUs) with time-based vesting over four years and 18,000 Performance Stock Units (PSUs) subject to performance conditions for the 2025-2026 period.
- Severance: In the event of a Change of Control followed by termination without Cause or resignation for Good Reason, Mr. Smith is entitled to 12 months of base salary, 100% acceleration of unvested equity, 100% of the annual bonus, and 12 months of COBRA reimbursement. Outside of a Change of Control, severance includes 9 months of base salary and 9 months of COBRA.
Abhishek Jain (Outgoing CFO):
- Severance: Entitled to a lump-sum cash payment equal to 12 months of base salary and 12 months of COBRA reimbursement, contingent on signing a release of claims.
- Consulting: Entered a consulting agreement effective August 7, 2025, through March 31, 2026, to assist with the transition. Outstanding equity awards will continue to vest during this term.
Outlook and Risks
The filing does not contain specific forward-looking guidance, risk factors, or management commentary regarding future financial performance beyond the standard disclaimers regarding the press release. The primary operational risk highlighted is the transition of financial leadership, though the company notes the departure was amicable and a transition plan is in place.
Key Facts for Investor Verification
- Verify the specific Q2 2025 financial results (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1) or the subsequent Form 10-Q, as they are not detailed in this 8-K text.
- Confirm the total cost of the CFO transition, including the 12-month severance for Mr. Jain and the equity grant value for Mr. Smith.
- Monitor the upcoming Form 10-Q for the full text of the Offer Letter, Change of Control Agreement, and Consulting Agreement.
- Assess the impact of the leadership change on the company's strategic execution and investor relations, given Mr. Smith's background in similar biotech/diagnostic sectors.